Premium
Cancer Therapy: Dual Intratumoral Redox/Enzyme‐Responsive NO‐Releasing Nanomedicine for the Specific, High‐Efficacy, and Low‐Toxic Cancer Therapy (Adv. Mater. 30/2018)
Author(s) -
Jia Xiaobo,
Zhang Yihua,
Zou Yu,
Wang Yao,
Niu Dechao,
He Qianjun,
Huang Zhangjian,
Zhu Weihong,
Tian He,
Shi Jianlin,
Li Yongsheng
Publication year - 2018
Publication title -
advanced materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.707
H-Index - 527
eISSN - 1521-4095
pISSN - 0935-9648
DOI - 10.1002/adma.201870217
Subject(s) - nanomedicine , nanocarriers , cancer therapy , cancer , materials science , prodrug , redox , cancer research , pharmacology , nanotechnology , drug delivery , medicine , nanoparticle , metallurgy
In article number 1704490 , Zhangjian Huang, Yongsheng Li, and co‐workers demonstrate a paradigm of dual intratumoral redox/enzyme‐responsive NO‐release nanomedicine for tumor‐specific and high‐efficacy cancer therapy by constructing a novel organic‐inorganic composite nanomedicine through encapsulating a GSTπ‐responsive NO‐releasing prodrug, NPQ, into a redox‐responsive organosilica nanocarrier, realizing the intratumoral GSH‐responsive organosilica biodegradation and subsequent controlled release of NO in response to intratumoral GSTπ.